Скачать или смотреть Plus Therapeutics' ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Metastatic #BreastCancer #LungCancer #Melanoma

Learn about the U.S. ReSPECT-LM clinical trial for leptomeningeal metastases:
https://ReSPECT-Trials.com/LM

Email questions about the U.S. ReSPECT-LM clinical trial for leptomeningeal metastases:
[email protected]

Recent news about the U.S. ReSPECT-LM clinical trial for leptomeningeal metastases:
https://ir.plustherapeutics.com/press...

Leptomeningeal Metastases (LM), also known as leptomeningeal carcinomatosis, is a late-stage cancer complication in which cancer cells spread from four primary cancers – breast, lung, melanoma and gastrointestinal – to the CNS. It is usually found in either the leptomeninges or cerebrospinal fluid (CSF), often goes undiagnosed due to a lack of symptoms, and causes neurological complications such as difficulty thinking, double vision, and headaches.

There is considerable variation in the resource-intensive treatment of LM, with no standard of care and usually significant healthcare costs at the one-year mark after diagnosis. Typically, treatment includes radiation therapy to the affected sites, followed by chemotherapy. The risk of significant side effects from entire neuroaxis radiation therapy generally outweighs the benefits in this relatively radioresistant tumor. Focal radiation therapy relieves neurological symptoms but has no significant effect on survival. Due to the relatively short median survival, today, patients must carefully evaluate whether they would prefer to prolong life with significant side effects or let the disease take its course while remaining relatively pain-free.